[Journal logo]

Volume 67 
Part 10 
Pages m1383-m1384  
October 2011  

Received 5 September 2011
Accepted 8 September 2011
Online 14 September 2011

Key indicators
Single-crystal X-ray study
T = 100 K
Mean [sigma](C-C) = 0.003 Å
R = 0.033
wR = 0.071
Data-to-parameter ratio = 17.9
Details
Open access

Bis{2-[(E)-(5-tert-butyl-2-hydroxyphenyl)diazenyl]benzoato}dimethyltin(IV)

aDepartment of Chemistry, North-Eastern Hill University, NEHU Permanent Campus, Umshing, Shillong 793 022, India, and bDepartment of Chemistry, University of Malaya, 50603 Kuala Lumpur, Malaysia
Correspondence e-mail: Edward.Tiekink@gmail.com

In the title diorganotin dicarboxylate, [Sn(CH3)2(C17H17N2O3)2], the tin(IV) atom is six-coordinated by four O atoms derived from asymmetrically coordinating carboxylate ligands, and two methyl-C atoms. The resulting C2O4 donor set defines a skew-trapezoidal bipyramid with the Sn-C bonds disposed over the weaker Sn-O bonds. Within each carboxylate ligand, the hydroxyl-H atom forms bifurcated O-H...(O,N) hydrogen bonds with carboxylate-O and azo-N atoms. The dihedral angles between the benzene rings in the two ligands are 10.44 (11) and 34.24 (11)°. In the crystal, centrosymmetric dimers are formed through pairs of Sn...O interactions [2.8802 (16) Å], and the dimers are linked into supramolecular layers in the ac plane by C-H...[pi] interactions.

Related literature

For background to the potential anti-cancer activity of related compounds, see: Basu Baul et al. (2011[Basu Baul, T. S., Paul, A., Pellerito, L., Scopelliti, M., Singh, P., Verma, P., Duthie, A., de Vos, D. & Tiekink, E. R. T. (2011). Invest. New Drugs, 29, 285-299.]). For the synthesis of the ligand, see: Basu Baul et al. (2008[Basu Baul, T. S., Paul, A., Arman, H. D. & Tiekink, E. R. T. (2008). Acta Cryst. E64, o2125.]). For related structural studies, see: Basu Baul et al. (2010[Basu Baul, T. S., Paul, A. & Tiekink, E. R. T. (2010). Z. Kristallogr. 225, 153-157.]). For a review of the structural chemistry of organotin carboxylates, see: Tiekink (1991[Tiekink, E. R. T. (1991). Appl. Organomet. Chem. 5, 1-23.]).

[Scheme 1]

Experimental

Crystal data
  • [Sn(CH3)2(C17H17N2O3)2]

  • Mr = 743.43

  • Monoclinic, P 21 /c

  • a = 9.6298 (1) Å

  • b = 31.8788 (4) Å

  • c = 11.0963 (1) Å

  • [beta] = 93.502 (1)°

  • V = 3400.05 (6) Å3

  • Z = 4

  • Mo K[alpha] radiation

  • [mu] = 0.80 mm-1

  • T = 100 K

  • 0.36 × 0.13 × 0.03 mm

Data collection
  • Bruker SMART APEXII diffractometer

  • Absorption correction: multi-scan (SADABS; Sheldrick, 1996[Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany.]) Tmin = 0.895, Tmax = 1

  • 26762 measured reflections

  • 7749 independent reflections

  • 6165 reflections with I > 2[sigma](I)

  • Rint = 0.031

Refinement
  • R[F2 > 2[sigma](F2)] = 0.033

  • wR(F2) = 0.071

  • S = 1.04

  • 7749 reflections

  • 434 parameters

  • H-atom parameters constrained

  • [Delta][rho]max = 0.55 e Å-3

  • [Delta][rho]min = -0.41 e Å-3

Table 1
Selected bond lengths (Å)

Sn-O1 2.1118 (16)
Sn-O2 2.6967 (16)
Sn-O4 2.1120 (16)
Sn-O5 2.4482 (16)
Sn-C35 2.081 (3)
Sn-C36 2.098 (2)

Table 2
Hydrogen-bond geometry (Å, °)

Cg1 is the centroid of the C25-C30 ring.

D-H...A D-H H...A D...A D-H...A
O3-H3...O1 0.84 2.49 3.142 (2) 136
O3-H3...N1 0.84 1.87 2.573 (2) 140
O6-H6...O5 0.84 2.20 2.877 (3) 137
O6-H6...N3 0.84 1.93 2.620 (3) 139
C10-H10...Cg1i 0.95 2.97 3.863 (2) 157
Symmetry code: (i) -x, -y+1, -z.

Data collection: APEX2 (Bruker, 2007[Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.]); cell refinement: SAINT (Bruker, 2007[Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.]); data reduction: SAINT; program(s) used to solve structure: SHELXS86 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); molecular graphics: ORTEP-3 (Farrugia, 1997[Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.]) and DIAMOND (Brandenburg, 2006[Brandenburg, K. (2006). DIAMOND. Crystal Impact GbR, Bonn, Germany.]); software used to prepare material for publication: SHELXL97.


Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: HB6399 ).


Acknowledgements

The financial support of the Department of Science and Technology, New Delhi, India (grant No. SR/S1/IC-03/2005,TSBB), the Council of Scientific and Industrial Research, New Delhi, India [grant No. 09/347/(0197)/2011/EMR I, for the award of a Senior Research Fellowship to AP] and the University Grants Commission, New Delhi, India, through SAP-DSA, Phase-III, are gratefully acknowledged.

References

Basu Baul, T. S., Paul, A., Arman, H. D. & Tiekink, E. R. T. (2008). Acta Cryst. E64, o2125.  [CSD] [CrossRef] [details]
Basu Baul, T. S., Paul, A., Pellerito, L., Scopelliti, M., Singh, P., Verma, P., Duthie, A., de Vos, D. & Tiekink, E. R. T. (2011). Invest. New Drugs, 29, 285-299.  [ISI] [CrossRef] [ChemPort]
Basu Baul, T. S., Paul, A. & Tiekink, E. R. T. (2010). Z. Kristallogr. 225, 153-157.  [CSD] [CrossRef]
Brandenburg, K. (2006). DIAMOND. Crystal Impact GbR, Bonn, Germany.
Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.  [CrossRef] [details]
Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.  [CrossRef] [details]
Tiekink, E. R. T. (1991). Appl. Organomet. Chem. 5, 1-23.  [CrossRef] [ChemPort] [ISI]


Acta Cryst (2011). E67, m1383-m1384   [ doi:10.1107/S1600536811036543 ]

This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.